Efficacy of convalescent plasma transfusion of COVID-19 survivors on the treatment of respiratory failure of these patients

Phase 2

Recruiting

• Conditions: COVID-19 Disease.; Coronavirus infection, unspecified site; B34.2

• Registration Number: IRCT20200406046968N2
• Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 18 May 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Age over 18 years
Confirmed COVID-19 clinically and positive PCR
Severe bilateral pulmonary involvement on CT scan or chest x-ray
Pao2/Fio2<300
Need for oxygen therapy or mechanical ventilation

Exclusion Criteria

Blood group incompatibility
Pregnancy

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Effect of convalescent plasma. Timepoint: Blood and plasma will be taken from patients who have been symptom free for 14-17 days. If it is less than 14 days, the donor should have 2 negative tests in two different days. Method of measurement: ELISA.

Secondary Outcome Measures

Name	Time	Method
Oxygenation. Timepoint: Daily until discharge or death. Method of measurement: ABG.;SOFA score. Timepoint: Daily until discharge or death. Method of measurement: Questionnaire.;Duration of mechanical ventilation. Timepoint: until discharge or death. Method of measurement: Questionnaire.;Duration of admission. Timepoint: Daily until discharge or death. Method of measurement: Questionnaire.;Mortality. Timepoint: Admission period. Method of measurement: patient's file.